The Experts below are selected from a list of 4320 Experts worldwide ranked by ideXlab platform
Ellen L Dally - One of the best experts on this subject based on the ideXlab platform.
-
Erigeron witches broom phytoplasma in brazil represents new subgroup vii b in 16s rrna gene group vii the ash yellows phytoplasma group
Plant Disease, 2002Co-Authors: Thereza S L Barros, R E Davis, Renato O Resende, Ellen L DallyAbstract:ABSTRACT A previously undescribed phytoplasma, Erigeron witches'-broom phytoplasma, was detected in diseased plants of Erigeron sp. and Catharanthus roseus exhibiting symptoms of witches'-broom and chlorosis in the state of Sao Paulo, Brazil. On the basis of restriction fragment length polymorphism (RFLP) analysis of 16S rDNA amplified in the polymerase chain reaction (PCR), Erigeron witches'-broom phytoplasma was classified in group 16SrVII (ash yellows phytoplasma group), new subgroup VII-B. Phylogenetic analysis of 16S rDNA sequences indicated that this phytoplasma represents a new lineage that is distinct from that of described strains of ash yellows phytoplasma. Erigeron witches'-broom phytoplasma is the first member of the ash yellows phytoplasma group to be recorded in Brazil.
Cheng Jia-yi - One of the best experts on this subject based on the ideXlab platform.
-
Metabolism and Pharmacological Mechanisms of Active Ingredients in Erigeron breviscapus.
Current Drug Metabolism, 2020Co-Authors: Fan Hua, Lin Peng, Kang Qiang, Zhao Zhi-long, Cheng Jia-yiAbstract:Background Erigeron breviscapus (Vant.) Hand-Mazz. is a plant species in the Compositae family. More than 10 types of compounds-such as flavonoids, caffeinate esters, and volatile oils-have been identified in Erigeron breviscapus; however, it remains unknown as to which compounds are associated with its clinical efficacy. In recent years, flavonoids and phenolic acids have been considered as the main effective components of Erigeron breviscapus. The metabolism and mechanisms of these compounds in vivo have been extensively studied to improve our understanding of the drug. Methods In the present review, we summarize the relationships among these compounds, their metabolites, and their pharmacodynamics. Many methods have been implemented to improve the separation and bioavailability of these compounds from Erigeron breviscapus. Results In China, Erigeron breviscapus has been used for many years. In recent years, through the study of its metabolism and the mechanisms of its effective components, the effects of Erigeron breviscapus in the treatment of various diseases have been extensively studied. Findings have indicated that Erigeron breviscapus improves cardiovascular and cerebrovascular function, and that one of its ingredients, scutellarin, has potential value in the treatment of Alzheimer's disease, cancer, diabetic vascular complications, and other conditions. In addition, phenolic acid compounds and their metabolites also play an important role in anti-oxidation, anti-inflammation, and improving blood lipids. Conclusion Erigeron breviscapus plays an important role in the prevention and treatment of cardiovascular/cerebrovascular diseases, neuroprotection, and cancer through many different mechanisms of action. Further investigation of its efficacious components and metabolites may provide more possibilities for the clinical application of traditional Chinese medicine and the development of novel drugs.
Jia-yi Cheng - One of the best experts on this subject based on the ideXlab platform.
-
Metabolism and Pharmacological Mechanisms of Active Ingredients in Erigeron breviscapus.
Current drug metabolism, 2021Co-Authors: Hua Fan, Peng Lin, Qiang Kang, Zhi-long Zhao, Ji Wang, Jia-yi ChengAbstract:Erigeron breviscapus (Vant.) Hand-Mazz. is a plant species in the Compositae family. More than ten types of compounds-such as flavonoids, caffeinate esters, and volatile oils-have been identified in Erigeron breviscapus; however, it remains unknown as to which compounds are associated with clinical efficacy. In recent years, flavonoids and phenolic acids have been considered as the main effective components of Erigeron breviscapus. The metabolism and mechanisms of these compounds in vivo have been extensively studied to improve our understanding of the drug. In the present review, we summarize the relationships among these compounds, their metabolites, and their pharmacodynamics. Many methods have been implemented to improve the separation and bioavailability of these compounds from Erigeron breviscapus. In China, Erigeron breviscapus has been used for many years. In recent years, through the study of its metabolism and the mechanisms of its effective components, the effects of Erigeron breviscapus in the treatment of various diseases have been extensively studied. Findings have indicated that Erigeron breviscapus improves cardiovascular and cerebrovascular function and that one of its ingredients, scutellarin, has potential value in the treatment of Alzheimer's disease, cancer, diabetic vascular complications, and other conditions. In addition, phenolic acid compounds and their metabolites also play an important role in anti-oxidation, anti-inflammation, and improving blood lipids. Erigeron breviscapus plays an important role in the prevention and treatment of cardiovascular/ cerebrovascular diseases, neuroprotection, and cancer through many different mechanisms of action. Further investigation of its efficacious components and metabolites may provide more possibilities for the clinical application of traditional Chinese medicine and the development of novel drugs. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
Thereza S L Barros - One of the best experts on this subject based on the ideXlab platform.
-
Erigeron witches broom phytoplasma in brazil represents new subgroup vii b in 16s rrna gene group vii the ash yellows phytoplasma group
Plant Disease, 2002Co-Authors: Thereza S L Barros, R E Davis, Renato O Resende, Ellen L DallyAbstract:ABSTRACT A previously undescribed phytoplasma, Erigeron witches'-broom phytoplasma, was detected in diseased plants of Erigeron sp. and Catharanthus roseus exhibiting symptoms of witches'-broom and chlorosis in the state of Sao Paulo, Brazil. On the basis of restriction fragment length polymorphism (RFLP) analysis of 16S rDNA amplified in the polymerase chain reaction (PCR), Erigeron witches'-broom phytoplasma was classified in group 16SrVII (ash yellows phytoplasma group), new subgroup VII-B. Phylogenetic analysis of 16S rDNA sequences indicated that this phytoplasma represents a new lineage that is distinct from that of described strains of ash yellows phytoplasma. Erigeron witches'-broom phytoplasma is the first member of the ash yellows phytoplasma group to be recorded in Brazil.
Fan Hua - One of the best experts on this subject based on the ideXlab platform.
-
Metabolism and Pharmacological Mechanisms of Active Ingredients in Erigeron breviscapus.
Current Drug Metabolism, 2020Co-Authors: Fan Hua, Lin Peng, Kang Qiang, Zhao Zhi-long, Cheng Jia-yiAbstract:Background Erigeron breviscapus (Vant.) Hand-Mazz. is a plant species in the Compositae family. More than 10 types of compounds-such as flavonoids, caffeinate esters, and volatile oils-have been identified in Erigeron breviscapus; however, it remains unknown as to which compounds are associated with its clinical efficacy. In recent years, flavonoids and phenolic acids have been considered as the main effective components of Erigeron breviscapus. The metabolism and mechanisms of these compounds in vivo have been extensively studied to improve our understanding of the drug. Methods In the present review, we summarize the relationships among these compounds, their metabolites, and their pharmacodynamics. Many methods have been implemented to improve the separation and bioavailability of these compounds from Erigeron breviscapus. Results In China, Erigeron breviscapus has been used for many years. In recent years, through the study of its metabolism and the mechanisms of its effective components, the effects of Erigeron breviscapus in the treatment of various diseases have been extensively studied. Findings have indicated that Erigeron breviscapus improves cardiovascular and cerebrovascular function, and that one of its ingredients, scutellarin, has potential value in the treatment of Alzheimer's disease, cancer, diabetic vascular complications, and other conditions. In addition, phenolic acid compounds and their metabolites also play an important role in anti-oxidation, anti-inflammation, and improving blood lipids. Conclusion Erigeron breviscapus plays an important role in the prevention and treatment of cardiovascular/cerebrovascular diseases, neuroprotection, and cancer through many different mechanisms of action. Further investigation of its efficacious components and metabolites may provide more possibilities for the clinical application of traditional Chinese medicine and the development of novel drugs.